Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LioCyx-M004 in Recurrent HBV-Related HCC Post-Transplant
NCT02719782Phase 1Unknown
- Sponsor
- Lion TCR
- Start
- Jul 2015
- Primary completion
- May 2019
- Modality
- Gene Editing, Bone Marrow HSCs, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liocyx-m in hepatocellular carcinoma (HCC), sponsored by Lion TCR. Primary endpoint: Safety of the TCR-T treatment. Status: unknown.
02
Drugs
liocyx-m
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02719782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02719782.